GlassScriptPhysician profile
Aaron Ivy Shaw
NPI 1104031814
$1,030.26
in general payments reported to CMS, 2019-2025
22 companies · $548 in 2025
The $548 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $215 · 2024: $267 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $188.53 | 2024 | Creo Fenestrated, Creo Threaded 4.75 Cocr |
| Medtronic, INC. | $135.17 | 2023 | Mazor X System |
| Exact Sciences Corporation | $97.49 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Nuvasive, INC. | $79.90 | 2023 | Reline |
| Amgen INC. | $71.32 | 2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $51.53 | 2025 | Airsupra, Farxiga |
| Pfizer INC. | $40.42 | 2025 | |
| Abbvie INC. | $32.97 | 2025 | |
| Lilly USA, LLC | $32.83 | 2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.67 | 2024 | Jardiance |
| Abiomed | $30.84 | 2025 | |
| Shield Therapeutics INC | $30.53 | 2025 | |
| Urgo Medical North America, LLC | $29.22 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Otsuka America Pharmaceutical, INC. | $28.89 | 2025 | Rexulti |
| Cranial Technologies, INC | $28.24 | 2025 | Doc Band |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $27.54 | 2025 | Onyda Xr, Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.62 | 2025 | Caplyta |
| Ascensia Diabetes Care US INC. | $16.72 | 2024 | |
| Sanofi-Aventis U.S. LLC | $15.81 | 2025 | |
| Dexcom, INC. | $14.95 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $14.43 | 2025 | |
| Phathom Pharmaceuticals, INC. | $11.64 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.